Exelixis $EXEL
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-310
RECRUITING4
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO62%
Delay Index: of 8 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.0 months). See all sponsors →
Open Exelixis on the live radar map → 📅 $EXEL readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Cabozantinib NCT03690388 |
P3 | Active, not recruiting | Differentiated Thyroid Cancer | 187 | 2020-08-19 (+2 mo) |
| COSMIC-312 NCT03755791 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 837 | 2021-11-30 (+16 mo) |
| COSMIC-313 NCT03937219 |
P3 | Active, not recruiting | Renal Cell Carcinoma | 855 | 2022-01-31 (+3 mo) |
| CONTACT-02 NCT04446117 |
P3 | Active, not recruiting | Metastatic Prostate Cancer; Prostate Adenocarcinoma | 575 | 2024-04-19 (+25 mo) |
| STELLAR-303 NCT05425940 |
P3 | Active, not recruiting | Colorectal Cancer | 901 | 2026-06-16 (+10 mo) |
| STELLAR-304 NCT05678673 |
P3 | Active, not recruiting | Non-Clear Cell Renal Cell Carcinoma | 317 | 2026-12-15 (+17 mo) |
| STELLAR-201 NCT07428616 |
P2 | Recruiting | Meningioma | 100 | 2028-02-29 |
| STELLAR-202 NCT07845786 |
P2 | Recruiting | Squamous Non-Small Cell Lung Cancer (NSCLC) | 60 | 2028-06-15 |
| STELLAR-305 NCT06082167 |
P2/3 | Active, not recruiting | Head and Neck Squamous Cell Carcinoma | 600 | 2028-08 (+15 mo) |
| STELLAR-311 NCT06943755 |
P2/3 | Recruiting | Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) | 440 | 2029-06-30 |
| STELLAR-316 NCT07750158 |
P3 | Recruiting | Colorectal Cancer | 600 | 2030-04-05 |
| Cabozantinib NCT07620574 |
P3 | Enrolling by invitation | Cancer; Renal Cell Carcinoma (RCC) | 5000 | 2030-05-31 |